Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,614 shares of the biotechnology company’s stock after selling 2,782 shares during the quarter. Wellington Management Group LLP’s holdings in Arrowhead Pharmaceuticals were worth $670,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ARWR. Vanguard Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after purchasing an additional 1,018,273 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $11,821,000. Aberdeen Group plc raised its stake in Arrowhead Pharmaceuticals by 138.4% during the 1st quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company’s stock worth $13,668,000 after acquiring an additional 622,752 shares in the last quarter. Two Sigma Investments LP raised its stake in Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company’s stock worth $14,934,000 after acquiring an additional 586,062 shares in the last quarter. Finally, Public Sector Pension Investment Board purchased a new stake in Arrowhead Pharmaceuticals in the first quarter valued at $5,094,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ARWR shares. B. Riley raised shares of Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Finally, Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Trading Down 1.4%

NASDAQ ARWR opened at $22.03 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The firm has a market cap of $3.05 billion, a PE ratio of -17.21 and a beta of 1.00. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $27.34. The firm’s fifty day moving average is $17.84 and its two-hundred day moving average is $16.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the previous year, the company posted ($1.38) EPS. Analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 9,389 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, August 15th. The shares were sold at an average price of $20.00, for a total value of $187,780.00. Following the transaction, the insider directly owned 262,122 shares in the company, valued at approximately $5,242,440. The trade was a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.